Bezlotoxumab and recurrent Clostridium difficile infection

New England Journal of Medicine

Volumn 376, Issue 16, 2017, Pages 1593-1594

  Sommer, Harriet ^a   Timsit, Jean François ^b   Wolkewitz, Martin ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTOXUMAB; BEZLOTOXUMAB; PLACEBO;

CLOSTRIDIUM DIFFICILE INFECTION; FOLLOW UP; HUMAN; INFECTION RISK; LETTER; RECURRENT INFECTION; CLOSTRIDIUM INFECTION; PEPTOCLOSTRIDIUM DIFFICILE; PSEUDOMEMBRANOUS COLITIS;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS;

EID: 85044514703     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1702531     Document Type: Letter

References (4)

1. Wolkewitz M, Cooper BS, Bonten MJ, Barnett AG, Schumacher M. Interpreting and comparing risks in the presence of competing events. BMJ 2014; 349: g5060.
2. Austin PC, Fine JP. Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement. Stat Med 2017; 36: 1203-9.
3. van Walraven C, McAlister FA. Competing risk bias was common in Kaplan-Meier risk estimates published in prominent medical journals. J Clin Epidemiol 2016; 69: 170-3.e8.
4. Andersen PK, Keiding N. Interpretability and importance of functionals in competing risks and multistate models. Stat Med 2012; 31: 1074-88.